Eli Lilly’s Retevmo Shows 83 Percent Drop in Cancer Recurrence Risk

Eli Lilly and Company (NYSE: LLY) announced that its targeted therapy Retevmo (selpercatinib) cut the risk of disease recurrence or death by 83 percent versus placebo in patients with early‑stage RET fusion‑positive non‑small cell lung cancer (NSCLC) in the Phase 3 LIBRETTO‑432 trial. The randomized study tested Retevmo as adjuvant therapy after surgery or radiation, aiming to prevent the cancer from coming back in patients with stage IB–IIIA disease.

LIBRETTO‑432 trial results at a glance

LIBRETTO‑432 enrolled 151 patients with early‑stage RET fusion‑positive NSCLC and randomized them 1:1 to Retevmo or placebo for up to three years after surgery or radiotherapy, with or without chemotherapy. In the primary analysis group (stage II–IIIA disease), Retevmo reduced the risk of recurrence or death by 83 percent, with a hazard ratio of 0.17 and a highly statistically significant p‑value of 0.0003.

At 24 months, event‑free survival was 92 percent for Retevmo versus 61 percent for placebo in stage II–IIIA patients, and similar benefits were seen across the broader IB–IIIA population. Median event‑free survival was not reached with Retevmo but was 31.8 months with placebo, and overall survival trends already favor selpercatinib despite limited follow‑up.

Safety profile and next regulatory steps

The safety profile of Retevmo in LIBRETTO‑432 was generally consistent with earlier studies, with the most common grade 3 or higher side effects being elevated liver enzymes (ALT and AST), which were manageable with dose adjustments. Lilly plans to submit the data to global health authorities, potentially seeking an expanded indication so Retevmo can be used as standard adjuvant therapy in early‑stage RET fusion‑positive NSCLC.

These results also reinforce RET fusions as a key biomarker in early lung cancer, alongside EGFR and ALK, and highlight the importance of comprehensive genomic testing at diagnosis to identify patients who might benefit from targeted adjuvant treatment.

Investor angle on Lilly and Retevmo

For Eli Lilly, the LIBRETTO‑432 data meaningfully expand the potential of Retevmo beyond advanced disease into the early‑stage, curative‑intent setting, where adjuvant therapies can be used for longer and in broader populations. If regulators approve the new use, Retevmo could secure a first‑mover advantage as the only selective RET inhibitor with strong Phase 3 evidence in early‑stage lung cancer, adding another high‑value oncology growth driver to Lilly’s already deep pipeline.